Mobile

A 4-week, phase-II, double-blind, placebo-controlled, randomized, parallel group, multi-centre study to assess the efficacy and tolerability/safety of inhaled AZD3199 once daily compared to 9 μg formo...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-011265-82

A 4-week, phase-II, double-blind, placebo-controlled, randomized, parallel group, multi-centre study to assess the efficacy and tolerability/safety of inhaled AZD3199 once daily compared to 9 μg formoterol bid and placebo in patients with moderate to severe COPD

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Primary objective is: • To compare the clinical efficacy of AZD3199 inhaled once daily with 9 μg formoterol twice daily and placebo over a 4-week treatment period in adults with chronic obstructive pulmonary disease (COPD)

Critère d'inclusion

  • Chronic Obstructive Pulmonary Disease (COPD)

Liens